Rapid advances in AI have significant implications for nuclear and biosecurity, including benefits and risks for nuclear weapons systems and the growing bioeconomy. Managing these new capabilities to ensure they aren’t misused to undermine strategic stability or cause a global biological catastrophe will require coordinated leadership, new guardrails, and innovative policy approaches.
The AIxBio field stands at a critical juncture where rapid capability advances are outpacing governance frameworks and safety measures. The next 18 months will likely prove pivotal in determining whether voluntary safety practices by AI companies, emerging evaluation frameworks, and international coordination efforts can keep pace with technological development.
Past Event
Virtual Report Launch
|
11:00 AM – 12:00 PM ET
Preventing global catastrophic biological risks (GCBRS)
Advances in biotechnology outpace national governments’ ability to provide needed oversight to prevent accidents or deliberate misuse of dangerous biological agents.
Past Project For as long as we have nuclear weapons, the United States must ensure they are safe, secure, and reliable.
NTI | bio experts will take part in several GHS2026 sessions, including a preview of findings from the forthcoming Africa Health Security (AHS) Index and a timely discussion on strengthening health security partnerships amid declining resources.
Since the AIxBio Horizon Scan Winter 2025-2026 published in March 2026, there has been steady, incremental progress across AI-enabled biological tools. Protein design tools have continued to improve, agentic coding tools have matured in ways that lower barriers to computational biology, and commercial AI companies are making significant investments in the life sciences.
The Summit can produce outcomes that strengthen U.S. national security and reduce global nuclear and biological risks
With AIxBio tools advancing faster than many experts predicted, new AIxBio Horizon Scan provides early insights to support stronger safety, security, and governance decisions.
The AIxBio field stands at a critical juncture where rapid capability advances are outpacing governance frameworks and safety measures. The next 18 months will likely prove pivotal in determining whether voluntary safety practices by AI companies, emerging evaluation frameworks, and international coordination efforts can keep pace with technological development.
Sign up for regular updates on innovative, real-world solutions to existential threats.
